Business Wire

MCF Corporate Finance Serves as Exclusive Financial Advisor to Seacross Marine AB (“SeaCross”), a Leading International Provider of Navigation Software for High-Speed Marine Operations, on Its Sale to Adelis Equity’s Defence Technology Group

Share

MCF Corporate Finance ("MCF") today announced its role as the exclusive financial advisor to the shareholders of SeaCross, a leading international provider of navigation software for high-speed marine operations, on its sale to Adelis Equity. This transaction marks the second investment in Adelis Equity’s recently established defence technology group.

"The decision to hire MCF as financial advisors was crucial in finding the best possible partner for SeaCross and supporting the company's growth journey ahead," said Harald Nilsonne, Founder and Chairman of SeaCross. "Throughout the process, they demonstrated an exceptional understanding of our business, software, and niche within the defence technology market. MCF’s strategic and steadfast advice, both before and during the process, ensured we found the right partner in Adelis."

SeaCross, renowned for its advanced high-speed marine navigation systems, is poised to enter a new phase of growth with Adelis Equity’s backing. The strategic partnership will enable SeaCross to further invest in and enhance its software and cutting-edge capabilities, supporting professional high-speed vessel operators worldwide.

MCF’s Advisory Role

MCF advised the shareholders of SeaCross in evaluating strategic options and ultimately securing a partnership that aligns with the company's vision and growth ambitions. This transaction reinforces MCF's strong track record in the defence and technology sectors, highlighting its expertise in advising business owners on structured sell-side transactions that deliver optimized outcomes.

About the Transaction

The acquisition of SeaCross by Adelis Equity represents the second investment in Adelis’ defence technology group, which aims to support Western and democratic countries in protecting people and societies, while enabling small- to mid-sized defence companies to scale and thrive. Adelis’ defence technology group focuses on building a portfolio of leading niche software and technology companies dedicated to defence and security.

About SeaCross Marine AB

Founded in Scandinavia, SeaCross has been at the forefront of high-speed marine navigation since its first product launch in 2006. The SeaCross system is known for its unique functionality, specifically designed for the most demanding environments and end users in the defence market. As a key international player in its niche, SeaCross serves a diverse customer base across the globe.

About Adelis Equity

Adelis is a growth partner for well-positioned companies in the Nordic and DACH regions. Adelis partners with management and/or owners to build businesses in growth segments and with strong market positions. Since raising its first fund in 2013, Adelis has been one of the most active investors in the Nordic middle-market, making 42 platform investments and more than 230 add-on acquisitions. Adelis manages approximately €3 billion in capital.

About MCF Corporate Finance

MCF Corporate Finance (MCF) is a leading M&A and debt advisory firm with offices in Frankfurt, Hamburg, Helsinki, London and Stockholm. Under the brand D.A. Davidson MCF International, we identify and execute transatlantic M&A transactions.

MCF has successfully structured and executed over 1,000 M&A and debt advisory transactions for multinational corporations, mid-sized companies, family offices, and private equity investors across its five core sectors: Business Services, Consumer, Industrials, Materials and Technology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240919561401/en/

Contacts

Deal Team Contacts:
Erik Pettersson, Partner | pettersson@mcfcorpfin.com
Ludvig Ahlinder, Director | ahlinder@mcfcorpfin.com
Vendela Palmquist, Associate | palmquits@mcfcorpfin.com

Media Contact:
Suzannah Burton, Marketing Director | burton@mcfcorpfin.com
MCF Corporate Finance, Stockholm Office

This press release is intended for distribution on Business Wire and other media
outlets. For additional details or to schedule interviews, please reach out to
the contacts listed above.

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mandate of BaFin’s special commissioner at flatexDEGIRO terminated18.10.2024 17:25:00 CEST | Press Release

Mandate of BaFin’s special commissioner at flatexDEGIRO terminated The mandate of the BaFin’s special commissioner at flatexDEGIRO Bank AG (the “Company”) was terminated on September 30, 2024, following the successful elimination of the serious deficiencies identified in the 2022 special audit by the Company and a positive review by the special commissioner. flatexDEGIRO AG made this announcement on October 18, 2024, following a corresponding decision by the German Federal Financial Supervisory Authority (BaFin). Oliver Behrens, CEO of flatexDEGIRO, said: “We have realigned and sustainably strengthened our organizational structures and processes in constructive cooperation with BaFin and the special commissioner. We are thereby closing a regulatory chapter and again increase our focus on our customers and important growth projects. My special thanks go to all employees who, under the leadership of Steffen Jentsch, member of the bank's management board, have made it possible to reach th

Biological Lattice Industries (BLI) Secures $1.8 Million Pre-Seed Funding Led by Uni.Fund to Democratize Biofabrication18.10.2024 16:00:00 CEST | Press Release

Biological Lattice Industries Corp. (BLI), a leading innovator in biofabrication and life sciences R&D, today announced the successful closing of a $1.8 million pre-seed investment round led by Greek venture capital firm Uni.Fund. In conjunction with this funding announcement , BLI is introducing its first all-in-one solution for biofabrication: BioLoom™, BLI's advanced multi-tool 3D bioprinter and Loominus Studio™, its unified software platform designed to revolutionize biofabrication workflows. BLI, a US startup with R&D operations in Greece, aims to radically simplify biofabrication for the global R&D community by providing intelligent, automated tools that streamline the design, fabrication, and testing of biomaterials. Biomaterials are critical for a wide array of biological applications. The applications range from advanced 3D cell culture systems for human biology emulation to the next-generation of resorbable medical devices and drug delivery systems for tissue trauma repair. “

Gurobi Brings Decision Intelligence Summit to Amsterdam18.10.2024 15:00:00 CEST | Press Release

Gurobi Optimization, LLC, the leader in decision intelligence technology, is set to host the first annual EMEAI Decision Intelligence Summit (“Gurobi Summit”) at Amsterdam’s Capital C on November 5-6, 2024. Following the success of last month’s inaugural summit for the Americas in Las Vegas, the EMEAI Summit will bring together operations researchers, data scientists, and business leaders from across the region to explore the latest advancements in mathematical optimization and decision intelligence. The Gurobi Summit will feature special presentations from companies such as Accenture and ICRON. Several of the company’s partners—including Decide4AI, Decision Labs, LTPLabs, and ORMAE—will also be present to showcase their solutions and insights. The two-day event will be packed with informative presentations, exciting customer case studies, and interactive learning opportunities. Day 1 will feature keynotes, technical presentations, and panel discussions. Day 2 will be dedicated to hand

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting18.10.2024 14:00:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place from October 18-22, 2024 in Philadelphia, Pennsylvania. Abstract A1187 — “Randomized, Placebo-Controlled, Phase 3 Trials of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor for Treatment of Acute Pain After Abdominoplasty or Bunionectomy” will be presented as an oral presentation on Sunday, October 20, during the “Best Abstract” session, which runs from 8:00-11:00 a.m. ET, as well as the Education session which runs on Monday, October 21, from 1:30-2:30 p.m. ET. Abstract A2074 — “A Phase 3, Single-Arm Study of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor For Treatment of Acute Pain From Surgical and Non-surgical Conditions” will be present

SLB Announces Third-Quarter 2024 Results18.10.2024 12:50:00 CEST | Press Release

SLB (NYSE: SLB) today announced results for the third quarter of 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241016795721/en/ The exterior of the SLB headquarters in Houston, Texas. (Photo: Business Wire) Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2024Jun. 30, 2024Sept. 30, 2023SequentialYear-on-yearRevenue $9,159 $9,139 $8,310 - 10% Income before taxes - GAAP basis $1,507 $1,421 $1,395 6% 8% Income before taxes margin - GAAP basis 16.5% 15.5% 16.8% 91 bps -33 bps Net income attributable to SLB - GAAP basis $1,186 $1,112 $1,123 7% 6% Diluted EPS - GAAP basis $0.83 $0.77 $0.78 8% 6% Adjusted EBITDA* $2,343 $2,288 $2,081 2% 13% Adjusted EBITDA margin* 25.6% 25.0% 25.0% 55 bps 54 bps Pretax segment operating income* $1,902 $1,854 $1,683 3% 13% Pretax segment operating margin* 20.8% 20.3% 20.3% 48 bps 51 bps Net income attributable to SLB, excluding charges & cr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye